Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants in pregnancy and congenital anomalies: Analysis of linked databases in Wales, Norway and Funen, Denmark

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Jordan, Sue ^a   Morris, Joan K ^b   Davies, Gareth I ^a   Tucker, David ^c   Thayer, Daniel S ^a   Luteijn, Johannes M ^b   Morgan, Margery ^c   Garne, Ester ^d   Hansen, Anne V ^e   Klungsøyr, Kari ^f,g   Engeland, Anders ^f,g   Boyle, Breidge ^h   Dolk, Helen ^h  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c PUBLIC HEALTH WALES   (United Kingdom)

^d KOLDING HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF BERGEN   (Norway)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ANTIDEPRESSANT AGENT;

ARTICLE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DENMARK; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; FETUS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREGNANCY; PREPREGNANCY CARE; STILLBIRTH; TERATOGENICITY; ABNORMALITIES, DRUG-INDUCED; ADULT; CHEMICALLY INDUCED; COMPLICATION; DEPRESSIVE DISORDER; FACTUAL DATABASE; HEART DEFECTS, CONGENITAL; NORWAY; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS; WALES;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DENMARK; DEPRESSIVE DISORDER; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; NORWAY; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS; WALES;

EID: 84999635682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165122     Document Type: Article

References (152)

1. Peters P, Miller R, Schaefer C. General commentary on drug therapy and drug risks in pregnancy. Pp.1-23 In: Schaefer C, Peters P, Miller R. (eds) Drugs During Pregnancy and Lactation.2015; Academic Press/Elsevier, London 3rd edition.
2. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, Study NBDP. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011; 51(2):264-70. doi: 10.1177/0091270010373928 PMID: 20663997.
3. Charlton RA, Jordan S, Pierini A, Garne E, Neville AJ, Hansen AV, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG. 2015; 122(7):1010-20. doi: 10.1111/1471-0528.13143 PMID: 25352424.
4. Olivier JD, Akerud H, Kaihola H, Pawluski JL, Skalkidou A, Högberg U, et al. The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. Front Cell Neurosci. 2013; 7:73. doi: 10.3389/fncel.2013.00073 PMID: 23734100.
5. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003 Jul; 60(7):720-6. doi: 10.1001/archpsyc.60.7.720 PMID: 12860776
6. Salisbury AL, Ponder KL, Padbury JF, Lester BM. Fetal effects of psychoactive drugs. Clin Perinatol. 2009; 36(3):595-619. doi: 10.1016/j.clp.2009.06.002 PMID: 19732616.
7. Daws LC, Gould GG. Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther. 2011; 131(1):61-79. doi: 10.1016/j.pharmthera.2011.03.013 PMID: 21447358.
8. Santos-Silva AJ, Cairrão E, Marques B, Verde I. Regulation of human umbilical artery contractility by different serotonin and histamine receptors. Reprod Sci. 2009; 16(12):1175-85. doi: 10.1177/1933719109343787 PMID: 19801536.
9. Ray S, Stowe ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014; 28(1):71-83. doi: 10.1016/j.bpobgyn.2013.09.005 PMID: 24211026.
10. Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod Toxicol. 2011; 32(4):484-9. doi: 10.1016/j.reprotox.2011.09. 004 PMID: 21963886.
11. Velasquez JC, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. Front Cell Neurosci. 2013; 7:47. doi: 10.3389/fncel.2013.00047 PMID: 23630464.
12. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996; 335(14):1010-5. doi: 10.1056/NEJM199610033351402 PMID: 8793924.
13. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Schønheyder HC, Sørensen HT. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents. 2005; 26(4):323-6. doi: 10.1016/j.ijantimicag.2005.06.017 PMID: 16144758.
14. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol. 2010; 2:29-36. PMID: 20865100.
15. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012; 2(3). doi: 10.1136/bmjopen-2012-001148 PMID: 22710132.
16. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015; 350:h1798. PMID: 25888213. doi: 10.1136/bmj.h1798
17. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009; 339: b3569. PMID: 19776103. doi: 10.1136/bmj.b3569
18. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007; 16(10):1086-94. doi: 10.1002/pds.1462 PMID: 17729378.
19. Ramos E, St-André M, Rey E, Oraichi D, Bérard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry. 2008; 192(5):344-50. doi: 10.1192/bjp. bp.107.042523 PMID: 18450657.
20. Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand. 2011; 123(4):266-75. doi: 10.1111/j.1600-0447.2011.01673.x PMID: 21261600.
21. Margulis AV, Abou-Ali A, Strazzeri MM, Ding Y, Kuyateh F, Frimpong EY, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf. 2013; 22(9):942-51. doi: 10.1002/pds.3462 PMID: 23733623.
22. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG. 2014; 121(12):1471-81. doi: 10.1111/1471-0528.12682 PMID: 24612301.
23. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007; 356(26):2675-83. doi: 10.1056/NEJMoa067407 PMID: 17596601.
24. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, Study NBDP. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015; 351: h3190. PMID: 26156519. doi: 10.1136/bmj.h3190
25. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007; 16(10):1075-85. doi: 10.1002/pds. 1463 PMID: 17729379.
26. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013; 47(11):1002-12. doi: 10.1177/0004867413492219 PMID: 23761574.
27. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40(10):1723-33. doi: 10.1017/S0033291709992194 PMID: 20047705.
28. Bérard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol. 2015; 212(6):795.e1-.e12. doi: 10.1016/j.ajog.2015.01.034 PMID: 25637841.
29. Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis. Daru. 2012; 20(1):75. doi: 10.1186/2008-2231-20-75 PMID: 23351929.
30. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013; 74(4):e293-308. doi: 10.4088/JCP.12r07966 PMID: 23656855.
31. Wemakor A, Casson K, Garne E, Bakker M, Addor MC, Arriola L, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol. 2015. doi: 10.1007/s10654-015-0065-y PMID: 26148560.
32. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014; 370(25):2397-407. doi: 10.1056/NEJMoa1312828 PMID: 24941178.
33. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011; 118(1):111-20. doi: 10.1097/AOG.0b013e318220edcc PMID: 21646927.
34. Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007; 80(1):18-27. doi: 10.1002/bdrb.20099 PMID: 17187388.
35. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, Study NBDP. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007; 356(26):2684-92. doi: 10.1056/NEJMoa066584 PMID: 17596602.
36. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011; 91(3):142-52. doi: 10.1002/bdra.20773 PMID: 21381184.
37. EUROCAT. EUROCAT European surveillance of congenital anomalies. Guide 1.3. EUROCAT European surveillance of congenital anomalies. Guide 1.3. EUROCAT Central Registry, University of Ulster, Newtownabbey, Co Antrim, UK. Available: http://www.eurocat-network.eu/content/EUROCATGuide-1.3.pdf. 2005. Accessed 12 October 2016.
38. EUROCAT. EUROCAT European surveillance of congenital anomalies. Guide 1.4. EUROCAT Central Registry, University of Ulster, Newtownabbey, Co Antrim, UK. Available: http://www.eurocatnetwork.eu/content/EUROCAT-Guide-1.4-Full-Guide.pdf. 2013. Accessed 26 February 2015.
39. Greenlees R, Neville A, Addor MC, Amar E, Arriola L, Bakker M, et al. Paper 6: EUROCAT member registries: organization and activities. Birth Defects Res A Clin Mol Teratol. 2011; 91 Suppl 1:S51-S100. doi: 10.1002/bdra.20775 PMID: 21381185.
40. Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsøyr K, et al. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf. 2014; 23(6):586-94. doi: 10.1002/pds.3613 PMID: 24664855.
41. EUROmediCAT. (EMC) 2015 Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants in Pregnancy and Congenital Anomalies: population cohort study using linked electronic data in 3 countries V2. Deliverable number 21. Available: http://www.EUROmediCAT.eu/publicationsandpresentations/publications.
42. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011; 39(7 Suppl):38-41. doi: 10.1177/1403494810394717 PMID: 21775349.
43. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010; 106 (2):86-94. doi: 10.1111/j.1742-7843.2009.00494.x PMID: 19961477.
44. Langhoff-Roos J, Krebs L, Klungsøyr K, Bjarnadottir RI, Källén K, Tapper AM, et al. The Nordic medical birth registers-a potential goldmine for clinical research. Acta Obstet Gynecol Scand. 2014; 93 (2):132-7. doi: 10.1111/aogs.12302 PMID: 24237585.
45. Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, Brown G, et al. The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res. 2009; 9:157. doi: 10.1186/1472-6963-9-157 PMID: 19732426.
46. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke JP, Ford DV, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak. 2009; 9:3. doi: 10.1186/1472-6947-9-3 PMID: 19149883.
47. Stats Wales, ELMS Welsh Government, Cardiff, Wales: Labour Force Survey, Quarterly Report issued 16th July, 2014, Reference ONS accessed on 23rd July, 2014. Available: https://statswales. wales.gov.uk/Catalogue/Business-Economy-and-Labour-Market/People-and-Work/Labour-Market-Summary/LabourMarketSummary-by-Measure-Age-UKCountry-Quarter. Accessed 12 October 2016.
48. World Bank Group, 2014, The World Bank-Working for a world free from poverty, Browse by country, accessed 16.1.14. Available: http://www.worldbank.org/en/country#N. Accessed 12 October 2016.
49. Hamer DM. Welsh Government Social Reaserch, 2013, Cardiff, Wales-Child Poverty strategy for Wales: Baseline indicators, accessed on 1st August, 2014. Available: http://wales.gov.uk/docs/caecd/research/130314-child-poverty-strategy-wales-baseline-indicators-en.pdf. Accessed 12 October 2016.
50. Bradshaw PJ. Changing Childhood in an a changing Europe: Interdisciplinary Workshop Report, Part XIII, Fondation Europeenne de la Science. Interdisciplinary Workshop, European Science Foundation Standing Committee for the Social Sciences de la Science Fondation. Available: http://www.york.ac. uk/inst/spru/research/pdf/Changing-Childhood.pdf. Accessed 12 October 2016.
51. European Commission (2008) Objective 1: Supporting development in less prosperous regions. Accessed 4th August, 2012. Available: http://ec.europa.eu/regional-policy/archive/objective1/index-en.htm. Accessed 12 October 2016.
52. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000; 85(1):11-28. PMID: 10674711.
53. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2015. Oslo, 2016. Available: http://www.whocc.no/filearchive/publications/2016-guidelines-web.pdf. Accessed 12 October 2016.
54. BNF. British National Formulary no.65. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London.; 2013.
55. Van Allen MI. Fetal vascular disruptions: mechanisms and some resulting birth defects. Pediatr Ann. 1981; 10(6):219-33. PMID: 7254912.
56. Wilffert B, Altena J, Tijink L, van Gelder MM, de Jong-van den Berg LT. Pharmacogenetics of druginduced birth defects: what is known so far? Pharmacogenomics. 2011; 12(4):547-58. doi: 10.2217/pgs.10.201 PMID: 21521026.
57. Yazdy MM, Mitchell AA, Louik C, Werler MM. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. Epidemiology. 2014; 25(6):859-65. doi: 10.1097/EDE. 0000000000000157 PMID: 25171134
58. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology. 1992; 45(4):361-7. doi: 10.1002/tera.1420450407 PMID: 1533958
59. Burdan F, Szumilo J, Dudka J, Korobowicz A, Klepacz R. Celosomy is associated with prenatal exposure to cyclooxygenase inhibitors. Pharmacol Res. 2006; 53(3):287-92. doi: 10.1016/j.phrs.2005.12. 006 PMID: 16460959
60. International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline for Good Clinincal Practice. Institute of Clinical Research, Marlow, Buckinghamshire. 1996. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed 2 January 2016). Number 56.
61. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006; 77(2):193-8. doi: 10.1136/jnnp.2005.074203 PMID: 16157661
62. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980; 68(1):122-40. PMID: 6985765
63. Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycook S, Pharoah PO, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ. 1997; 315(7103):275-8. PMID: 9274545
64. Schaefer C, Peters PWJ, Miller RK. Drugs during pregnancy and lactation: treatment options and risk assessment. 2nd ed. ed. Amsterdam; London: Elsevier; 2007.
65. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. Circulation. 2013; 128(6):583-9. doi: 10.1161/CIRCULATIONAHA.112.001054 PMID: 23812182
66. Jordan S, Charlton R, Tingay K, Thayer D, Davies G, Morgan M, et al. SSRI use in pregnancy: a study in 6 European databases. The International Marcé Society For Perinatal Mental Health Biennial Scientific Conference, Swansea University, Swansea, Wales, UK. Abstract Booklet The Marce Society. Arch Womens Ment Health (2015) 18:269-408 P.368 10.1007/S00737-014-0488-6.
67. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004; 23(9):1351-75. doi: 10.1002/sim.1761 PMID: 15116347
68. Simes R. An improved Bonferroni procedure for multiple tests of significance. Biometrica1986. p. 751-4.
69. Benjamini Y, Hachberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. 1995. p. 289-300.
70. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP. 2011.
71. Torfs CP, Christianson RE. Maternal risk factors and major associated defects in infants with Down syndrome. Epidemiology. 1999; 10(3):264-70. PMID: 10230836
72. IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
73. NCCMH. (National Collaborating Centre for Mental Health) 2014 Antenatal and postnatal mental health: Clinical management and service guidance, updated edition, National Clinical Guideline 192. Published by The British Psychological Society and The Royal College of Psychiatrists, London. Available: https://www.nice.org.uk/guidance/cg192. Accessed 12 October 2016.
74. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003; 160(5):993-6. doi: 10.1176/appi.ajp.160.5.993 PMID: 12727706.
75. Pop A, Lupu DI, Cherfan J, Kiss B, Loghin F. Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors. Clujul Med. 2015; 88(3):381-5. doi: 10.15386/cjmed-474 PMID: 26609273.
76. Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med. 2010; 164(5):444-51. doi: 10.1001/archpediatrics.2010.51 PMID: 20439795.
77. Tracy TS, Venkataramanan R, Glover DD, Caritis SN, Units NIfCHaHDNoM-F-M. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005; 192(2):633-9. doi: 10.1016/j.ajog.2004.08.030 PMID: 15696014.
78. Willner P, Scheel-Krüger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev. 2013; 37(10 Pt 1):2331-71. doi: 10.1016/j.neubiorev.2012.12.007 PMID: 23261405.
79. Wadhwa PD, Glynn L, Hobel CJ, Garite TJ, Porto M, Chicz-DeMet A, et al. Behavioral perinatology: biobehavioral processes in human fetal development. Regul Pept. 2002; 108(2-3):149-57. PMID: 12220739.
80. Sljivic S, Kamenov B, Maglajlic S, Djordjevic V, Stojkovic-Eferica I, Stojanovic M, et al. Possible interactions of genetic and immuno-neuro-endocrine regulatory mechanisms in pathogenesis of congenital anomalies. Med Hypotheses. 2006; 67(1):57-64. doi: 10.1016/j.mehy.2005.07.037 PMID: 16574341.
81. Wadhwa PD, Garite TJ, Porto M, Glynn L, Chicz-DeMet A, Dunkel-Schetter C, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol. 2004; 191(4):1063-9. doi: 10.1016/j.ajog.2004.06.070 PMID: 15507922.
82. Bukowski R, Hansen NI, Willinger M, Reddy UM, Parker CB, Pinar H, et al. Fetal growth and risk of stillbirth: a population-based case-control study. PLoS Med. 2014; 11(4):e1001633. doi: 10.1371/journal.pmed.1001633 PMID: 24755550.
83. Carmichael SL, Ma C, Tinker S, Rasmussen SA, Shaw GM, Study NBDP. Maternal stressors and social support as risks for delivering babies with structural birth defects. Paediatr Perinat Epidemiol. 2014; 28(4):338-44. doi: 10.1111/ppe.12123 PMID: 24697924.
84. Hannerfors AK, Hellgren C, Schijven D, Iliadis SI, Comasco E, Skalkidou A, et al. Treatment with serotonin reuptake inhibitors during pregnancy is associated with elevated corticotropin-releasing hormone levels. Psychoneuroendocrinology. 2015; 58:104-13. doi: 10.1016/j.psyneuen.2015.04.009 PMID: 25978816.
85. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005; 25(9):595-604. doi: 10.1038/sj.jp.7211352 PMID: 16015372.
86. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 2008; 115(2):283-9. doi: 10.1111/j.1471-0528.2007.01518.x PMID: 17903222.
87. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014; 36(1):13-8. doi: 10.1016/j.genhosppsych.2013.08.002 PMID: 24094568.
88. Huybrechts KF, Bateman BT, Hernandez-Diaz S. Maternal Antidepressant Use and Persistent Pulmonary Hypertension of the Newborn-Reply. JAMA. 2015; 314(12):1294. doi: 10.1001/jama.2015. 10048 PMID: 26393857.
89. Gardosi J, Kady SM, McGeown P, Francis A, Tonks A. Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study. BMJ. 2005; 331(7525):1113-7. doi: 10.1136/bmj. 38629.587639.7C PMID: 16236774
90. Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA. 2013; 309(1):48-54. doi: 10.1001/jama.2012.153812 PMID: 23280224.
91. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Lander AR, Afzal S, et al. SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry. 2013; 170(3):299-304. doi: 10.1176/appi.ajp.2012.11081251 PMID: 23361562.
92. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008; 83(1):68-76. doi: 10.1002/bdrb.20144 PMID: 18293409.
93. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010; 36(3):518-44. doi: 10.1093/schbul/sbn107 PMID: 18787227.
94. Reis M, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open. 2013; 3(2). doi: 10.1136/bmjopen-2012-002166 PMID: 23427202.
95. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015; 125(5):1224-35. doi: 10.1097/AOG.0000000000000759 PMID: 25932852.
96. Latendresse G, Ruiz RJ, Wong B. Psychological distress and SSRI use predict variation in inflammatory cytokines during pregnancy. Open J Obstet Gynecol. 2013; 3(1A):184-91. doi: 10.4236/ojog. 2013.31A034 PMID: 24524011.
97. Eke AC, Saccone G, Berghella V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG. 2016 May 30. doi: 10.1111/1471-0528.14144 PMID: 27239775.
98. Räisänen S, Lehto SM, Nielsen HS, Gissler M, Kramer MR, Heinonen S. Risk factors for and perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002-2010 in Finland. BMJ Open. 2014; 4(11):e004883. doi: 10.1136/bmjopen-2014-004883 PMID: 25398675.
99. Klemetti A, Saxén L. Prospective versus retrospective approach in the search for environmental causes of malformations. Am J Public Health Nations Health. 1967; 57(12):2071-5. PMID: 6070247.
100. Barzo B, Moretti M, Mareels G, van Tittelboom T, G K. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet: 354: 1700-1. 1999. PMID: 10568577
101. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011; 64(12):1311-6. doi: 10.1016/j.jclinepi.2011. 06.004 PMID: 21802902.
102. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. J Clin Epidemiol. 2013; 66 (9):964-72. doi: 10.1016/j.jclinepi.2013.02.011 PMID: 23800534.
103. Knudsen TM, Hansen AV, Garne E, Andersen AM. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth. 2014; 14:333. doi: 10.1186/1471-2393-14-333 PMID: 25258023.
104. Gadkari AS, McHorney CA. Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin. 2010; 26(3):683-705. doi: 10.1185/03007990903550586 PMID: 20078320.
105. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication nonadherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010; 25(4):284-90. doi: 10.1007/s11606-010-1253-9 PMID: 20131023.
106. van Geffen EC, Gardarsdottir H, van Hulten R, van Dijk L, Egberts AC, Heerdink ER. Initiation of antidepressant therapy: do patients follow the GP's prescription? Br J Gen Pract. 2009; 59(559):81-7. doi: 10.3399/bjgp09X395067 PMID: 19192372.
107. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993; 307(6908):846-8. PMID: 8401129
108. Pierpont ME, Basson CT, Benson DW, Gelb BD, Giglia TM, Goldmuntz E, et al. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007; 115(23):3015-38. doi: 10.1161/CIRCULATIONAHA.106.183056 PMID: 17519398.
109. Jordan S, Watkins A, Storey M, Allen SJ, Brooks CJ, Garaiova I, et al. Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a longitudinal analysis. PLoS One. 2013; 8(7):e67912. doi: 10.1371/journal.pone.0067912 PMID: 23874465.
110. Alwan S, Chambers CD. Findings from the National Birth Defects Prevention Study: Interpretation and translation for the clinician. Birth Defects Res A Clin Mol Teratol. 2015; 103(8):721-8. doi: 10.1002/bdra.23394 PMID: 26109026.
111. Kendrick T, King F, Albertella L, Smith PW. GP treatment decisions for patients with depression: an observational study. Br J Gen Pract. 2005; 55(513):280-6. PMID: 15826435.
112. Angermeyer MC, Matschinger H, Link BG, Schomerus G. Public attitudes regarding individual and structural discrimination: two sides of the same coin? Soc Sci Med. 2014; 103:60-6. doi: 10.1016/j. socscimed.2013.11.014 PMID: 24507911.
113. Demidenko E. Sample size determination for logistic regression revisited. Stat Med. 2007; 26 (18):3385-97. doi: 10.1002/sim.2771 PMID: 17149799.
114. Talbot J, Keisu M, Stahle L. Clinical Trials-Collecting Saftey Data and Establishing the Adverse Drug Reaction Profile pp.215-290 (chapter 4) In: Talbot J., Aronson J. (eds) Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 2012; Wiley-Blackwell, Chichester (6th edition).
115. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012; 7(7):e41174. doi: 10.1371/journal.pone.0041174 PMID: 22911755.
116. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990; 1(1):43-6. PMID: 2081237.
117. Golder S, Loke YK, Bland M. Comparison of pooled risk estimates for adverse effects from different observational study designs: methodological overview. PLoS One. 2013; 8(8):e71813. doi: 10.1371/journal.pone.0071813 PMID: 23977151.
118. Bradford-Hill A. The environment and disease: association or causation.: Proceedings of the Royal Society of Medicine.; 1965. p. 295-300.
119. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016 Apr; 31(4):337-50. doi: 10.1007/s10654-016-0149-3 PMID: 27209009
120. BNF. British National Formulary no.71. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London.; 2016.
121. United Nations. The Millennium development goals report 2007. New York: United Nations, 2007.
122. Wisner K, Schaefer C. Psychotropic Drugs pp. 293-339 In: Schaefer C, Peters P, Miller R. (eds) Drugs During Pregnancy and Lactation.2015; Academic Press/Elsevier, London 3rd edition.
123. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013; 127(2):94-114. doi: 10.1111/acps.12042 PMID: 23240634.
124. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013; 70(4):436-43. doi: 10.1001/jamapsychiatry.2013.684 PMID: 23446732.
125. Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009; 86 (6):672-7. doi: 10.1038/clpt.2009.201 PMID: 19890255.
126. Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013; 347:f4877. PMID: 23965506. doi: 10.1136/bmj.f4877
127. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354(6):579-87. doi: 10.1056/NEJMoa052744 PMID: 16467545.
128. Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014; 348:f6932. PMID: 24429387. doi: 10.1136/bmj.f6932
129. Handal M, Skurtveit S, Furu K, Hernandez-Diaz S, Skovlund E, Nystad W, et al. Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study. BJOG. 2015. doi: 10.1111/1471-0528.13582 PMID: 26374234.
130. Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology. 2011; 22(6):848-54. PMID: 21900825.
131. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008; 5(2):e45. doi: 10.1371/journal.pmed.0050045 PMID: 18303940.
132. Menchetti M, Rucci P, Bortolotti B, Bombi A, Scocco P, Kraemer HC, et al. Moderators of remission with interpersonal counselling or drug treatment in primary care patients with depression: randomised controlled trial. Br J Psychiatry. 2014; 204(2):144-50. doi: 10.1192/bjp.bp.112.122663 PMID: 24311553.
133. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009; 31(5):403-13. doi: 10.1016/j.genhosppsych.2009.04.003 PMID: 19703633.
134. NCCMH. (National Collaborating Centre for Mental Health) (2007) Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance. Published by the British Psychological Society and the Royal College of Psychiatrists, London
135. Pearlstein T. Depression during Pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015; 29(5):754-64. doi: 10.1016/j.bpobgyn.2015.04.004 PMID: 25976080.
136. Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A, McCallum M, Howard LM, Pariante CM. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014 15; 384(9956):1800-19. doi: 10.1016/S0140-6736(14)61277-0. PMID: 25455250.
137. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Radford K, Martinovic J, Ross LE. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013 Apr; 74(4):e321-41. doi: 10.4088/JCP.12r07968 PMID: 23656857
138. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010 Oct; 67(10):1012-24. doi: 10.1001/archgenpsychiatry.2010.111 PMID: 20921117
139. McDonagh M, Matthews A, Phillipi C, Romm J, Peterson K, Thakurta S, et al. Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence Report/Technology Assessment No. 216. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 14-E003-EF. Agency for Healthcare Research and Quality, Rockville, MD (July 2014) Available: https://www.effectivehealthcare.ahrq.gov/search-for-guidesreviews-and-reports/?pageaction=displayproduct&productid=1927. Accessed 12 October 2016.
140. Hippocrates (Translated by Jones WHS). (1923). The Hippocratic Corpus, Epidemics, book I, sect. XI. Loeb Classical Library, Cambridge, UK and London, Heineman. Available: http://archive.org/stream/hippocrates01hippuoft/hippocrates01hippuoft-djvu.txt. Accessed Accessed 12 October 2016.
141. Hutton C, Gunn J. Do longer consultations improve the management of psychological problems in general practice? A systematic literature review. BMC Health Serv Res. 2007; 7:71. doi: 10.1186/1472-6963-7-71 PMID: 17506904.
142. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006; 295(5):499-507. doi: 10.1001/jama.295.5.499 PMID: 16449615.
143. Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ. 2015; 350:h517. PMID: 25693810. doi: 10.1136/bmj.h517
144. Einarson A. Publishing statistically significant results with questionable clinical importance: focus on antidepressant use in pregnancy. J Clin Psychiatry. 2012; 73(11):1443-6. doi: 10.4088/JCP. 12com08192 PMID: 23218161.
145. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011; 8(5): e1001026. doi: 10.1371/journal.pmed.1001026 PMID: 21559325.
146. Dietz PM, Homa D, England LJ, Burley K, Tong VT, Dube SR, Bernert JT. Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of reproductive age in the United States. Am J Epidemiol. 2011 Feb 1; 173(3):355-9. doi: 10.1093/aje/kwq381 PMID: 21178103
147. Flower A, Shawe J, Stephenson J, Doyle P. Pregnancy planning, smoking behaviour during pregnancy, and neonatal outcome: UK Millennium Cohort Study. BMC Pregnancy Childbirth. 2013; 13:238. doi: 10.1186/1471-2393-13-238 PMID: 24354748.;
148. Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015; 351:h6019. PMID: 26645251. doi: 10.1136/bmj.h6019
149. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L. Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ. 2009; 338: b1673. PMID: 19436079. doi: 10.1136/bmj.b1673
150. Li Y, Hua Y, Fang J, Wang C, Qiao L, Wan C, et al. Performance of different scan protocols of fetal echocardiography in the diagnosis of fetal congenital heart disease: a systematic review and metaanalysis. PLoS One. 2013; 8(6):e65484. doi: 10.1371/journal.pone.0065484 PMID: 23750263.
151. American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 656 Summary: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol. 2016; 127(2):418. doi: 10.1097/AOG.0000000000001309 PMID: 26942384.
152. Whitworth M, Bricker L, Mullan C. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev. 2015;(7:):CD007058. PMID: 26171896.